Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Molnupiravir inhibits SARS-CoV-2 variants including Omicron in the hamster model
Kyle Rosenke, Atsushi Okumura, Matthew Lewis, et al.
JCI Insight (2022) Vol. 7, Iss. 13
Open Access | Times Cited: 37

Showing 1-25 of 37 citing articles:

Antiviral Efficacy and Safety of Molnupiravir Against Omicron Variant Infection: A Randomized Controlled Clinical Trial
Rongrong Zou, Ling Peng, Dan Shu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 42
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs
Sho Iketani, David D. Ho
Cell chemical biology (2024) Vol. 31, Iss. 4, pp. 632-657
Open Access | Times Cited: 7
Combined molnupiravir-nirmatrelvir treatment improves the inhibitory effect on SARS-CoV-2 in macaques
Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, et al.
JCI Insight (2022) Vol. 8, Iss. 4
Open Access | Times Cited: 30
Bioluminescence imaging reveals enhanced SARS-CoV-2 clearance in mice with combinatorial regimens
Irfan Ullah, Fanny Escudié, Ivan Scandale, et al.
iScience (2024) Vol. 27, Iss. 3, pp. 109049-109049
Open Access | Times Cited: 6
Evolution of Omicron lineage towards increased fitness in the upper respiratory tract in the absence of severe lung pathology
Arthur Wickenhagen, Meaghan Flagg, Julia R. Port, et al.
Nature Communications (2025) Vol. 16, Iss. 1
Open Access
Natural infection of SARS-CoV-2 variant XBB.1.9.1.4.1 in laboratory Syrian hamsters
Chunmao Zhang, Zhendong Guo
Microbiology Spectrum (2025)
Open Access
Potential Anti-SARS-CoV-2 Prodrugs Activated by Phosphorylation and Their Role in the Aged Population
Vivek P. Chavda, Divya Teli, Pankti C. Balar, et al.
Molecules (2023) Vol. 28, Iss. 5, pp. 2332-2332
Open Access | Times Cited: 13
Potential of green tea EGCG in neutralizing SARS-CoV-2 Omicron variant with greater tropism toward the upper respiratory tract
Zhichao Zhang, Meng Hao, Xiangchun Zhang, et al.
Trends in Food Science & Technology (2022) Vol. 132, pp. 40-53
Open Access | Times Cited: 20
N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody
Arne Zibat, Xiaoxiao Zhang, Antje Dickmanns, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107786-107786
Open Access | Times Cited: 10
Molnupiravir for intra-household prevention of COVID-19: The MOVe-AHEAD randomized, placebo-controlled trial
Sady Alpizar, José Accini, Duane C. Anderson, et al.
Journal of Infection (2023) Vol. 87, Iss. 5, pp. 392-402
Open Access | Times Cited: 9
Evaluation of molnupiravir (EIDD-2801) efficacy against SARS-CoV-2 in the rhesus macaque model
Dylan M. Johnson, Trevor Brasel, Shane Massey, et al.
Antiviral Research (2022) Vol. 209, pp. 105492-105492
Open Access | Times Cited: 14
Pathogenesis and virulence of coronavirus disease: Comparative pathology of animal models for COVID-19
Natalie M. Kirk, Yuying Liang, Hinh Ly
Virulence (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 2
New conjugates based on N4-hydroxycytidine with more potent antiviral efficacy in vitro than EIDD-2801 against SARS-CoV-2 and other human coronaviruses
Andrei E. Siniavin, Vladimir А. Gushchin, Natal’ya S. Shastina, et al.
Antiviral Research (2024) Vol. 225, pp. 105871-105871
Open Access | Times Cited: 2
Further preclinical characterization of molnupiravir against SARS-CoV-2: Antiviral activity determinants and viral genome alteration patterns
Paul-Rémi Petit, Franck Touret, Jean‐Sélim Driouich, et al.
Heliyon (2024) Vol. 10, Iss. 10, pp. e30862-e30862
Open Access | Times Cited: 2
Indole-3-carbinol in vitro antiviral activity against SARS-Cov-2 virus and in vivo toxicity
Federica Centofanti, Tonino Alonzi, Andrea Latini, et al.
Cell Death Discovery (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 12
Current understanding of nucleoside analogs inhibiting the SARS-CoV-2 RNA-dependent RNA polymerase
Tiantian Xu, Lu Zhang
Computational and Structural Biotechnology Journal (2023) Vol. 21, pp. 4385-4394
Open Access | Times Cited: 7
Combined Molnupiravir and Nirmatrelvir Treatment Improves the Inhibitory Effect on SARS-CoV-2 in Rhesus Macaques
Kyle Rosenke, Matt C. Lewis, Friederike Feldmann, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 10
Evolution of Omicron lineage towards increased fitness in the upper respiratory tract in the absence of severe lung pathology
Arthur Wickenhagen, Meaghan Flagg, Julia R. Port, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Uncovering the Contrasts and Connections in PASC: Viral Load and Cytokine Signatures in Acute COVID-19 versus Post-Acute Sequelae of SARS-CoV-2 (PASC)
Brandon Compeer, Tobias R. Neijzen, S.F.L. van Lelyveld, et al.
Biomedicines (2024) Vol. 12, Iss. 9, pp. 1941-1941
Open Access | Times Cited: 1
Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir against mortality, hospitalization, and in-hospital outcomes among community-dwelling, ambulatory COVID-19 patients during the BA.2.2 wave in Hong Kong: an observational study
Carlos King Ho Wong, Ivan Chi Ho Au, Kristy T.K. Lau, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 8
Current state-of-the-art and potential future therapeutic drugs against COVID-19
Ailong Sha, Yi Liu, Haiyan Hao
Frontiers in Cell and Developmental Biology (2023) Vol. 11
Open Access | Times Cited: 4
Virologic Outcomes with Molnupiravir in Non-hospitalized Adult Patients with COVID-19 from the Randomized, Placebo-Controlled MOVe-OUT Trial
Julie Strizki, Jay A. Grobler, Nicholas Murgolo, et al.
Infectious Diseases and Therapy (2023) Vol. 12, Iss. 12, pp. 2725-2743
Open Access | Times Cited: 4
Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
Henrik Berg Rasmussen, Peter Riis Hansen
Viruses (2023) Vol. 15, Iss. 11, pp. 2151-2151
Open Access | Times Cited: 3
Combinatorial Regimens Augment Drug Monotherapy for SARS-CoV-2 Clearance in Mice
Irfan Ullah, Fanny Escudié, Ivan Scandale, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top